Insmed Inc (INSM)vsOpus Genetics, Inc. (IRD)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
IRD
Opus Genetics, Inc.
$4.75
+5.32%
HEALTHCARE · Cap: $312.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 4172% more annual revenue ($606.42M vs $14.20M). IRD leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
IRD
Avoid17
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while IRD is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
IRD generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is an innovative biotechnology company specializing in gene therapies for rare retinal diseases that impact vision. Leveraging cutting-edge research and proprietary gene-editing technologies, Opus aims to fulfill significant unmet medical needs through transformative solutions that restore sight. With a dedicated focus on ocular health, the company is positioned as a frontrunner in the biotech industry, appealing to investors interested in pioneering healthcare advancements. Supported by ongoing clinical trials and strategic collaborations, Opus Genetics is well-equipped to improve patient outcomes while generating substantial value for its stakeholders.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?